Abstract
Introduction Recent meta-analysis of the association between herpesvirus infection and dementia concluded that the evidence for an association to date is insufficient.
Methods 2.5 million individuals aged ≥65 years were followed up using linked electronic health records in four national observational cohort studies. Exposure and outcome were classified using coded data from primary and secondary care. Data were analyzed using survival analysis with time-dependent covariates.
Results Results were heterogeneous, with a tendency towards decreased dementia risk in individuals exposed to antiherpetic medication. Associations were not affected by treatment number, herpes subtype, dementia subtype, or specific medication. In one cohort, individuals diagnosed with herpes but not exposed to antiherpetic medication were at higher dementia risk.
Discussion Short-term antiherpetic medication is not markedly associated with incident dementia. Because neither dementia subtype nor herpes subtype modified the association, the small but significant decrease in dementia incidence with antiherpetic adminstration may reflect confounding and misclassification.
Competing Interest Statement
Karel Kostev and Hartmut Richter are employees of IQVIA (Germany)
Funding Statement
We gratefully acknowledge financial support (grant VIRADE 2019) from the Benter Foundation, Pittsburgh, USA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Analysis of data from SAIL and eDRIS was granted under IGRP 0938 and PBPP 1819-0297, respectively. Analysis of data from IMS Disease Analyzer and DNR did not require specific governance approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Access to the underlying routinely collected electronic health records is governed by the different data provider (SAIL, eDRIS, IQVIA (epidemiology) and the Danish national research institute).
